A Randomized Phase IIB Open Label Study of Nivolumab or Nivolumab in Combination with Ipilimumab Versus Bevacizumab in Adult Subjects with Recurrent Glioblastoma (GBM)
Investigator: Nicholas Butowski, MD
Sponsor: Bristol-Myers Squibb Company
Location(s): United States
The purposes of the study are to understand the
- Safety and tolerability of Nivolumab and Nivolumab in combination with Ipilimumab in a safety lead-in phase (Cohort 1, 1b) and
- The safety, tolerability and efficacy of Nivolumab versus Bevacizumab (Cohort 2) in patients diagnosed with recurrent glioblastoma (GBM).